Adma Biologics Inc (ADMA) concluded trading on Wednesday at a closing price of $19.50, with 3.34 million shares of worth about $65.16 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 207.09% during that period and on October 02, 2024 the price saw a loss of about -1.37%. Currently the company’s common shares owned by public are about 226.06M shares, out of which, 225.18M shares are available for trading.
Stock saw a price change of 0.05% in past 5 days and over the past one month there was a price change of 17.68%. Year-to-date (YTD), ADMA shares are showing a performance of 331.42% which increased to 452.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.06 but also hit the highest price of $20.37 during that period. The average intraday trading volume for Adma Biologics Inc shares is 4.79 million. The stock is currently trading 4.97% above its 20-day simple moving average (SMA20), while that difference is up 17.74% for SMA50 and it goes to 102.72% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ: ADMA) currently have 226.06M outstanding shares and institutions hold larger chunk of about 78.06% of that.
The stock has a current market capitalization of $4.55B and its 3Y-monthly beta is at 0.62. PE ratio of stock for trailing 12 months is 138.69, while it has posted earnings per share of $0.14 in the same period. It has Quick Ratio of 2.80 while making debt-to-equity ratio of 0.75. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADMA, volatility over the week remained 3.56% while standing at 4.79% over the month.
Stock’s fiscal year EPS is expected to rise by 471.15% while it is estimated to increase by 35.75% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 19, 2023 offering a Strong buy rating for the stock and assigned a target price of $5 to it. Coverage by Mizuho stated Adma Biologics Inc (ADMA) stock as a Buy in their note to investors on October 13, 2022, suggesting a price target of $5 for the stock. On November 11, 2021, Raymond James Upgrade their recommendations, while on November 09, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $4.50. Stock get a Buy rating from Jefferies on June 04, 2019.
